Clinical Trial Update: A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 [Phase 1]

View source ↗

Summary

First-in-human Phase 1 dose-escalation and expansion study of the antibody-drug conjugate BYON3521 in solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• BYON3521

Snippet

Sponsor: Byondis B.V. | Conditions: Solid Tumor | Phase 1 | Status: COMPLETED